The goal of this clinical trial is to learn if receiving peer recovery support (support services provided by trained "peers" with lived experience of addiction and recovery) improves retention in medication treatment among people with opioid use disorder. The main question it aims to answer is: does peer recovery support improve retention in medication treatment for opioid use disorder?
Researchers will compare two groups: (1) standard care combined with a peer recovery support program, and (2) standard care alone, to see if peer recovery support works to improve retention in medication treatment for opioid use disorder.
Participants will: visit clinics as they normally would to receive standard care (medication treatment for opioid use disorder); complete two questionnaires - one when they start treatment and one 6 months later; and agree to let researchers use information from their medical record. Participants in group 1 will also be invited to meet with a peer recovery support specialist for up to 6 months.
Adult ≥ 18 years of age
Initiated medication for opioid use disorder treatment in past 45 days in a Geisinger outpatient clinic
Willing and able to give informed consent
Received medication for opioid use disorder treatment at a Geisinger outpatient clinic in the 90-day period prior to the treatment initiation date
Not proficient in English
Parallel
Peer recovery support to enhance patient engagement in medication for opioid use disorder treatment
BehavioralThe intervention adds a peer recovery support (PRS) program to standard outpatient medication for opioid use disorder treatment and medical care. The PRS program will entail meeting one-on-one with a peer recovery specialist over a 6-month period, who will utilize their lived experience with substance use and recovery to provide emotional, informational, instrumental, and affiliational support to participants.
6-month treatment retention
Data will come from the electronic health records. Retention will be defined as a participant not having a lapse in days' supply of medication for opioid use disorder treatment (buprenorphine, buprenorphine-naloxone, or naltrexone) within the 6-month follow-up period that is greater than 30 days.
Length of time in treatment
Data will come from the electronic health records. Length of time in treatment will be determined by summing days' supply of consecutive orders for medications for opioid use disorder treatment(buprenorphine, buprenorphine- naloxone, or naltrexone). Treatment will be considered ended if a participant has a gap in supply of more than 30 days.
Click on the lead sponsor to view all of their trials.
Geisinger Clinic
Lead sponsor
UConn Health
Collaborator
